Journal of the Korean society of biological therapies in psychiatry (생물치료정신의학)

The Korean Society of Biological Therapies in Psychiatry (대한생물치료정신의학회)
권호 표지

Quality of Life of Antipsychotic-Induced Hyperprolactinemia in Patients with Schizophrenia

항정신병약물로 유발된 고프로락틴혈증을 가진 조현병 환자의 삶의 질

  • Woo, Seonjin (Department of Psychiatry, School of Medicine, Kyungpook National University) ;
  • Jin, Bo-Hyun (Department of Psychiatry, School of Medicine, Kyungpook National University) ;
  • Won, Seunghee (Department of Psychiatry, School of Medicine, Kyungpook National University)
  • 우선진 (경북대학교 의과대학 정신건강의학교실) ;
  • 진보현 (경북대학교 의과대학 정신건강의학교실) ;
  • 원승희 (경북대학교 의과대학 정신건강의학교실)
  • Received : 2018.05.09
  • Accepted : 2018.09.20
  • Published : 2018.10.31

⟨ Previous Next ⟩

Abstract

Objectives : Antipsychotic-induced hyperprolactinemia causes physical symptoms, such as amenorrhea, galactorrhea, gynecomastia, sexual dysfunction, and bone density loss, as well as psychiatric symptoms, such as depression and cognitive impairments. This study aimed to clarify the associations among hyperprolactinemia caused by antipsychotics in patients with schizophrenia, psychiatric pathology, and psychosocial factors. Methods : Ninety-nine patients with schizophrenia in the psychiatry department of a university hospital were registered between 2015 and 2017. All participants were assessed using structured questionnaires to elucidate psychopathology, social function, quality of life, and hyperprolactinemia-related side effects. The standard levels for hyperprolactinemia were 24ng/mL for women and 20ng/mL for men. Results : The average prolactin levels were $73.45{\pm}49.37ng/mL$ in patients with hyperprolactinemia and $9.16{\pm}6.42ng/mL$ in those without hyperprolactinemia. The average prolactin level in women was significantly higher than that in men(p=0.04). Risperidone was most commonly administered in patients with hyperprolactinemia(58.1%, p<0.01), while aripiprazole was most commonly administered in those without hyperprolactinemia(44.7%, p<0.01). Patients with hyperprolactinemia had significantly higher Positive and Negative Syndrome Scale(p=0.03) and Patient Health Questionnaire-9(p=0.05) scores and had significantly lower Social and Occupational Functioning Assessment Scale(p=0.04) and Strauss-Carpenter Levels of Functioning Scale(p=0.03) scores than patients without hyperprolactinemia. There were no significant differences in side effects or quality of life between the two groups. Conclusion : These findings demonstrate that hyperprolactinemia confers negative effects on depression and social function, but does not directly affect the quality of life. These results suggest that patients with schizophrenia who take antipsychotics that increase prolactin or cause side effects of hyperprolactinemia need to be assessed and receive interventions for depression.

Keywords

References

  1. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;165:18-21. https://doi.org/10.1192/S0007125000293161
  2. Awad AG, Voruganti LN. Quality of life and new antipsychotics in schizophrenia are patients better off? Int J Soc Psychiatry 1999;45:268-75. https://doi.org/10.1177/002076409904500405
  3. Franz M, Lis S, Pl K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422-5. https://doi.org/10.1192/bjp.170.5.422
  4. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87. https://doi.org/10.1001/archpsyc.63.10.1079
  5. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia. Drugs 2004;64:2291-314. https://doi.org/10.2165/00003495-200464200-00003
  6. Milano W, Walter D'Acunto C, De Rosa M, Festa M, Milano L, Petrella C, et al. Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Rev Recent Clin Trials 2011;6:52-64. https://doi.org/10.2174/157488711793980138
  7. Won SH, Kwak KP. Correlations between Hyperprolactinemia and Bone Mineral Density, Bone Markers in Women with Chronic Schizophrenia. J Korean Soc Biol Ther Psychiatry 2006;12:204-14.
  8. Kellner R, Buckman MT, Fava GA, Pathak D. Hyperprolactinemia, distress, and hostility. Am J Psychiatry 1984;141:759-763. https://doi.org/10.1176/ajp.141.6.759
  9. Koo JS, Won SH, Kwak KP. Comparison and correlation of cognitive functions, prolactin, estrogen in women with schizophrenia on risperidone, olanzapine. Korean J Schizophr Res 2007;10:53-61.
  10. Park YM, Lee HJ, Choo JS. Serious short-term and longterm effects of antipsychotic-induced hyperprolactinemia. Korean J Psychopharmacol 2009;20:167-80.
  11. Medici CR, Vestergaard CH, Hjorth P, Hansen MV, Shanmuganathan JW, Viuff AG, et al. Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia. Int J Soc Psychiatry 2016;62:12-20. https://doi.org/10.1177/0020764015585330
  12. Shargh NA, Rostami B, Kosari B, Toosi Z, Majelan GA. Study of relationship between depression and quality of life in patients with chronic schizophrenia. Glob J Health Sci 2016;8:224-9. https://doi.org/10.5539/gjhs.v8n9p224
  13. Kaneda Y. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia. Clin Neuropharmacol 2003;26:182-4. https://doi.org/10.1097/00002826-200307000-00006
  14. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003;28:69-82.
  15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders(DSM-$5^{(R)}$): American Psychiatric Pub; 2013.
  16. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64: 663-7. https://doi.org/10.4088/JCP.v64n0607
  17. Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale(PANSS) for schizophrenia. Schizophrenia bull 1987;13:261-76. https://doi.org/10.1093/schbul/13.2.261
  18. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-8. https://doi.org/10.1016/0920-9964(92)90003-N
  19. Kim YK, Won SD, Lee KM, Choi HS, Jang HS, Lee BH, et al. A study on the reliability and validity of the Korean version of the Calgary Depression Scale for Schizophrenia (K-CDSS). J Korean Neuropsychiatr Assoc 2005;44:446-55.
  20. Kroenke K, Spitzer R, Williams J. The PHQ-9: validity of a brief depression severity measure. Research Support. Non-US Gov't 2001.
  21. Park SJ, Choi HR, Choi JH, Kim KW, Hong JP. Reliability and validity of the Korean version of the patient health questionnaire-9(PHQ-9). Anxiety and Mood 2010;6:119-24.
  22. Rosenberg M. The measurement of self-esteem, society and the adolescent self-image. Princeton 1965:16-36.
  23. Jeon BJ. Self-esteem: A test of its measurability. Seoul: Yonsei Nonchong; 1974. p. 11.
  24. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia: Characteristics of outcome. Arch Gen Psychiatry 1972;27:739-46. https://doi.org/10.1001/archpsyc.1972.01750300011002
  25. Kim CY. Assessment tool of mental disease. Seoul: Hana Press; 2001. p. 120.
  26. Hogan TP, Awad A, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83. https://doi.org/10.1017/S0033291700050182
  27. Yoon BH, Bahk WM, Lee KU, Hong CH, Ahn JK, Kim MK. Psychometric properties of Korean version of drug attitude inventory(KDAI-10). Korean J Psychopharmacol 2005;16:480-7.
  28. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000;177:42-6. https://doi.org/10.1192/bjp.177.1.42
  29. Kim JH, Yim SJ, Min SK, Kim SE, Son SJ, Wild DJ, et al. The Korean version of 4th revision of schizophrenia quality of life scale: validation study and relationship with PANSS. J Korean Neuropsychiatr Assoc 2006;45:401-10.
  30. Naber D, Walther A, Kircher T, Hayek D, Holzbach R. Subjective effects of neuroleptics predict compliance. prediction of neuroleptic treatment outcome in schizophrenia: Springer; 1994:85-98.
  31. Yoon JS, Kook SH, Lee HY, Lee C, Paik IH. The development of a Korean modification of the scale to measure subjective well-being under neuroleptic treatment (KmSWN). J Korean Neuropsychiatr Assoc 2000;39:987-98.
  32. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 2001;51:317-24.
  33. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28:55-68.
  34. Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. Clin Psychiatry 2004;65:1491-8. https://doi.org/10.4088/JCP.v65n1108
  35. Lee KH, Kang SH, Kang GY, Kim KH, Kim KK, Soh M, et al. The Prevalence of Hyperprolactinemia and Amenorrhea and the Association with Sexual Dysfunction in Schizophrenic Patients with Antipsychotics. J Korean Neuropsychiatr Assoc 2009;48:423-9.
  36. Kane JM, Meltzer HY, Carson JW, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68:213-23. https://doi.org/10.4088/JCP.v68n0206
  37. Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak S, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 2004;14:593-600. https://doi.org/10.1089/cap.2004.14.593
  38. Lee KH, Kang SH, Kang GY, Kim KH, Kim KK, Soh M, et al. The prevalence of hyperprolactinemia and amenorrhea and the association with sexual dysfunction in schizophrenic patients with antipsychotics. J Korean Neuropsychiatr Assoc 2009;48:423-9.
  39. Buckman M. Psychological distress in hyperprolactinemic women. prolactin: basic and clinical correlates. Liviana press; 1985. p. 601-68.
  40. Roy A. Suicidal behavior in schizophrenics. depression in schizophrenics: Springer; 1989:137-52
  41. Touraine P, Plu-Bureau G, Beji C, Mauvais-Jarvis P, Kuttenn F. Long-term follow-up of 246 hyperprolactinemic patients. Acta Obstet Gynecol Scand 2001;80:162-8. https://doi.org/10.1034/j.1600-0412.2001.080002162.x
  42. Shim JC, Kong BG, Jung DU, Kang JW, Oh MK. Adjunctive treatment with aripiprazole for risperidone-induced amenrrhea. Korean J Psychopharmacol 2011;22:34-9.
  43. Bargiota S, Bonotis K, Messinis I, Angelopoulos N. The effects of antipsychotics on prolactin levels and women's menstruation. Schizophr Res Treatment 2013;2013:1-10.
  44. Margariti M, Ploumpidis D, Economou M, Christodoulou GN, Papadimitriou GN. Quality of life in schizophreniad spectrum disorders: associations with insight and psychopathology. Psychiatry Res 2015;225:695-701. https://doi.org/10.1016/j.psychres.2014.11.016
  45. von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl 2009;438:15-21.
  46. Park SY, Shin S, Kim E. Prescription Pattern of Atypical Antipsychotics in a University Psychiatric Ward.: 11-Year Observational Study. Korean J Schizophr Res 2016;19:68-77. https://doi.org/10.16946/kjsr.2016.19.2.68